Autologous stem cell transplantation in myelodysplastic syndromes.

@article{Witte2007AutologousSC,
  title={Autologous stem cell transplantation in myelodysplastic syndromes.},
  author={Theo J M de Witte and Stefan Suciu and Ronald Brand and Petra Muus and Nicolaus Kr{\"o}ger},
  journal={Seminars in hematology},
  year={2007},
  volume={44 4},
  pages={274-7}
}
Allogeneic stem cell transplantation (SCT) is the treatment of choice for the majority of young patients with myelodysplasia (MDS) who have a histocompatible donor (sibling or unrelated donor). For some patients lacking a human leukocyte antigen (HLA)-compatible donor, chemotherapy followed by autologous SCT may be a reasonable alternative, especially for patients with therapy-related MDS/acute myeloid leukemia (AML). A substantial number of candidates may not be eligible for autologous SCT due… CONTINUE READING